Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Becton, Dickinson and Company (BDX)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
222.83-3.29 (-1.45%)
At close: 04:00PM EDT
224.00 +1.17 (+0.53%)
After hours: 05:02PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inside Bar (Bullish)

Inside Bar (Bullish)

Previous Close226.12
Open227.13
Bid220.42 x 800
Ask226.01 x 1000
Day's Range222.61 - 228.63
52 Week Range222.61 - 277.29
Volume1,619,756
Avg. Volume946,504
Market Cap63.55B
Beta (5Y Monthly)0.59
PE Ratio (TTM)33.86
EPS (TTM)6.58
Earnings DateNov 02, 2022 - Nov 07, 2022
Forward Dividend & Yield3.48 (1.56%)
Ex-Dividend DateSep 08, 2022
1y Target Est278.27
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-21% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for BDX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Becton, Dickinson and Company
    Analyst Report: Becton, Dickinson And Co.Headquartered in Franklin Lakes, New Jersey, BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, industry, and the general public. Its operations consist of three worldwide business segments: BD Medical, BD Life Sciences, and BD Interventional.
    Rating
    Fair Value
    Economic Moat
    10 days agoArgus Research
View more
Advertisement
Advertisement